Related Experiment Videos
Pharmacogenetics and blood dyscrasias
1Strategic Operations, Clinical and Regulatory Development, Merck Research Laboratories, Blue Bell, PA 19422, USA.
European Journal of Haematology. Supplementum
|January 1, 1996
Summary
Genetic variations influence drug metabolism and toxicity, increasing the risk of severe adverse drug reactions. Molecular screening can identify individuals at risk, enabling personalized medicine approaches to prevent adverse drug reactions.
Area of Science:
- Pharmacogenetics
- Toxicology
- Clinical Pharmacology
Background:
- Pharmacogenetic differences significantly impact drug metabolism and response.
- These variations can lead to severe idiosyncratic adverse drug reactions (iADRs) such as neutropenia, agranulocytosis, and aplastic anemia.
- Deficiencies in drug-metabolizing enzymes or detoxification pathways can result in toxic metabolite accumulation or immune responses.
Purpose of the Study:
- To explore the role of pharmacogenetic variations in the risk of idiosyncratic adverse drug reactions.
- To highlight how altered drug metabolism and detoxification pathways contribute to drug toxicity.
- To discuss the potential of molecular screening for predicting and preventing iADRs.
Main Methods:
- Review of existing literature on pharmacogenetics and adverse drug reactions.
- Analysis of mechanisms involving drug metabolism (e.g., 6-mercaptopurine to 6-thioguanine nucleotides) and detoxification (e.g., glutathione conjugation).
- Discussion on the implications of inherited enzyme deficiencies.
Main Results:
- Inherited deficiencies in drug-metabolizing enzymes can lead to the formation of directly toxic metabolites or reactive electrophilic metabolites.
- Impaired detoxification pathways, such as glutathione conjugation, increase susceptibility to adverse drug events.
- Specific examples illustrate how genetic variations dictate drug metabolite toxicity.
Conclusions:
- Pharmacogenetic factors are critical determinants of idiosyncratic adverse drug reactions.
- Understanding these genetic underpinnings is essential for predicting and mitigating drug toxicity.
- Molecular screening tools offer a promising avenue for personalized risk assessment and prevention of iADRs.